Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer,
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported
Quick Look: ASML reports mixed Q1 2024 results: Sales €5.29B, profits decline 40.39%. Christophe Fouquet appointed as new CEO; maintains €27.6B full-year sales forecast. China sales hit €2B, 49% of total; U.S.-led export curbs affect semiconductor industry. ASML expands
Quick Look: Halper Sadeh LLC investigates the fairness of Encore Wire’s sale to Prysmian at $290/share. Concerns about underpayment and adequacy of shareholder information. Deal valued at $4.2 billion; includes a premium over recent share prices. The market responded
Quick Look: Saudi & Qatari indices are down, with Saudi -1.8% and Qatari -1.6% due to Iran-Israel tensions. Bahrain’s index is up 0.9%, contrasting regional downtrends. Brent crude at $90.45, a six-month high amid conflict. As investors seek stability,
Quick Look: Cronos Group stock fell by 2.53%, closing at $3.47. Trading volume below average with cautious investor stance. Annual shares are up by 25.27% despite market downturns. Earnings reveal a net margin of -84.15% and EPS of -$0.19.
Asian shares slumped on Friday after China reported a set of weak data, fuelling fresh worries of a slowdown in the world’s second biggest economy and leaving investors fretting over the wider impact of a yet to be solved US-China trade dispute. Read more here!
Asian stock markets started the week on a cautious step following the soft economic data from China and Europe added to evidence of cooling global growth and reinforced anxiety over the broadening impact of international trade frictions. Read more!
China stocks on Wednesday recorded lower at the trade close. The losses in sectors such as Telecoms, Mobile, and Life Insurance have dragged the shares lower. The Shanghai Composite dropped 0.26%, hitting a fresh one-month low at the Shanghai
Asian stocks rose on Friday after Wall Street finished the volatile trade in positive territory, adding to the previous session’s big gains, although lingering investor anxiety support safe-haven currencies such as yen. Read more here!
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported by rising stock prices, ‘Buy’ ratings from Citigroup and Stifel, and robust institutional support. Summit
Quick Look: ASML reports mixed Q1 2024 results: Sales €5.29B, profits decline 40.39%. Christophe Fouquet appointed as new CEO; maintains €27.6B full-year sales forecast. China sales hit €2B, 49% of total; U.S.-led export curbs affect semiconductor industry. ASML expands US presence; anticipates industry rebound by 2025 with continuous
Quick Look: Halper Sadeh LLC investigates the fairness of Encore Wire’s sale to Prysmian at $290/share. Concerns about underpayment and adequacy of shareholder information. Deal valued at $4.2 billion; includes a premium over recent share prices. The market responded positively, with significant stock price increases for both companies.
Quick Look: Saudi & Qatari indices are down, with Saudi -1.8% and Qatari -1.6% due to Iran-Israel tensions. Bahrain’s index is up 0.9%, contrasting regional downtrends. Brent crude at $90.45, a six-month high amid conflict. As investors seek stability, gold peaks at $2400, a new record. Mixed global
Quick Look: Cronos Group stock fell by 2.53%, closing at $3.47. Trading volume below average with cautious investor stance. Annual shares are up by 25.27% despite market downturns. Earnings reveal a net margin of -84.15% and EPS of -$0.19. Analysts hold a ‘Moderate Buy’ despite challenges. Cronos Group
Quick Look: Summit Therapeutics’s key drug in advanced trials for lung cancer, leveraging dual pathway inhibition. With a market cap of $3.73 billion and liquidity ratios at 6.97, despite a PE of -29.88. Supported